Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 7, 2013, Pages 1117-1127

  Chen, Jiong ^a   Chen, Long Jiang ^a   Xia, Yun Lian ^a   Zhou, Hang Cheng ^a   Yang, Ren Bao ^a   Wu, Wen ^a   Lu, Yin ^a   Hu, Li Wei ^a   Zhao, Yue ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Matrix assisted laser desorption ionization time of flight mass spectrometry; Pancreatic ductal adenocarcinoma; Proteomics; Transthyretin; Two dimensional difference gel electrophoresis

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; PREALBUMIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AGED; BLOOD PROTEINS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREALBUMIN; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 84879239006     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1422-4     Document Type: Article

References (45)

1. Bunger S, Laubert T, Roblick UJ, Habermann JK (2011) Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 137:375-389
2. Chen R, Pan S, Aebersold R, Brentnall TA (2007a) Proteomics studies of pancreatic cancer. Proteomics Clin Appl 1:1582-1591
3. Chen R, Pan S, Cooke K et al (2007b) Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34:70-79 (Pubitemid 46045723)
4. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I (2008) Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS ONE 3:e2899
5. Dowling P, Shields W, Rani S et al (2008) Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction. Electrophoresis 29:4141-4149
6. Ehmann M, Felix K, Hartmann D et al (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34:205-214 (Pubitemid 46294796)
7. Escher N, Kob R, Kaatz M, Melle C, Hipler C, von Eggeling F (2011) Confirmation of the biological significance of transthyretin as a biomarker for cutaneous T-cell lymphoma by its protein interaction partners. Mol Med Rep 4:157-161
8. Ferrone CR, Brennan MF, Gonen M et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701-706
9. Fiedler GM, Leichtle AB, Kase J et al (2009) Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 15:3812-3819
10. Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266-270 (Pubitemid 46488663)
11. Gouvea IE, Kondo MY, Assis DM et al (2012) Studies on the peptidase activity of transthyretin (TTR). Biochimie. doi: 10.1016/j.biochi.2012.09.014
12. Guerreiro A, da Costa G, Gomes RA et al (2012) α-Synuclein aggregation in the saliva of familial transthyretin amyloidosis: a potential biomarker. Amyloid 19:74-80
13. Hanash S (2003) Disease proteomics. Nature 422:226-232 (Pubitemid 36362760)
14. Harsha HC, Kandasamy K, Ranganathan P et al (2009) A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6:e1000046
15. Ingenbleek Y, Young V (1994) Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 14:495-533 (Pubitemid 24261848)
16. Jacobsson B (1989) In situ localization of transthyretin-mRNA in the adult human liver, choroid plexus and pancreatic islets and in endocrine tumours of the pancreas and gut. Histochemistry 91:299-304 (Pubitemid 19122874)
17. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
18. Kelly JW, Colon W, Lai Z et al (1997) Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 50:161-181 (Pubitemid 27449488)
19. Lee JJ, Maeng CH, Baek SK et al (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70:205-210
20. Liu YP, Hu SW, Wu ZF et al (2011) Proteomic analysis of human serum from diabetic retinopathy. Int J Ophthalmol 4:616-622
21. Liz MA, Faro CJ, Saraiva MJ, Sousa MM (2004) Transthyretin, a new cryptic protease. J Biol Chem 279:21431-21438 (Pubitemid 38656553)
22. Liz MA, Fleming CE, Nunes AF et al (2009) Substrate specificity of transthyretin: identification of natural substrates in the nervous system. Biochem J 419:467-474
23. Lv S, Gao J, Zhu F et al (2011) Transthyretin, identified by proteomics, is overabundant in pancreatic juice from pancreatic carcinoma and originates from pancreatic islets. Diagn Cytopathol 39:875-881
24. Pan S, Chen R, Crispin DA et al (2011) Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 10:2359-2376
25. Refai E, Dekki N, Yang SN et al (2005) Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling. Proc Natl Acad Sci USA 102:17020-17025 (Pubitemid 41692676)
26. Rosty C, Goggins M (2002) Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 16:37-52 (Pubitemid 34578625)
27. Saminathan R, Bai J, Sadrolodabaee L et al (2010) VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker. PLoS ONE 5:e15064
28. Sandanayake NS, Sinclair J, Andreola F et al (2011) A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 105:1370-1378
29. Schreiber G (2002) The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 175:61-73 (Pubitemid 35276587)
30. Schultz K, Nilsson K, Nielsen JE et al (2010) Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Eur J Neurol 17:456-460
31. Schweigert FJ, Sehouli J (2005) Transthyretin, a biomarker for nutritional status and ovarian cancer. Cancer Res 65:1114 (Pubitemid 40216476)
32. Schweigert FJ, Wirth K, Raila J (2004) Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci 2:5 (Pubitemid 41630801)
33. Stathis A, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163-172
34. Su Y, Jono H, Misumi Y et al (2012) Novel function of transthyretin in pancreatic alpha cells. FEBS Lett. doi: 10.1016/j.febslet.2012.10.025
35. Tannu NS, Hemby SE (2006) Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling. Nat Protoc 1:1732-1742 (Pubitemid 46778055)
36. Tirumalai RS, Chan KC, Prieto DA et al (2003) Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2:1096-1103
37. Tosh D, Shen CN, Slack JM (2002) Differentiated properties of hepatocytes induced from pancreatic cells. Hepatology 36:534-543 (Pubitemid 34977163)
38. Trenchevska O, Kamcheva E, Nedelkov D (2011) Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics 11:3633-3641
39. Tuitoek PJ, Ziari S, Tsin AT, Rajotte RV, Suh M, Basu TK (1996) Streptozotocin-induced diabetes in rats is associated with impaired metabolic availability of vitamin A (retinol). Br J Nutr 75:615-622 (Pubitemid 26142026)
40. Valsecchi ME, Holdbrook T, Leiby BE et al (2012) Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? Bmc Cancer 12:104
41. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378:607-620
42. Xue A, Scarlett CJ, Chung L et al (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer 103:391-400
43. Xue A, Gandy RC, Chung L, Baxter RC, Smith RC (2012) Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Pancreatology 12:124-129
44. Yan L, Tonack S, Smith R et al (2009) Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res 8:142-148
45. Yu KH, Rustgi AK, Blair IA (2005) Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 4:1742-1751 (Pubitemid 41464802)